CClinicalTrials.gg
Status unknownNCT03188315Updated Jun 15, 2017

Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

An interventional study of HPV oncogenes in DNA Virus Infections, sponsored by Heba Momen kamel. Status unknown. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-15.

Sponsored by Heba Momen kamel · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jun 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world.

Tumor viruses can be classified into two groups based on their genetic material;

  1. DNA tumor viruses:

    1. Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses).
    2. Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses).
  2. RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV").

There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV).

The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV.

Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.

Read the detailed description

Study subjects:

  1. Inclusion criteria:

    • Age: 18 - 65 years old.
    • Women who are positive for HPV diagnosed by routine screening. Women willing to participate in the study and sign an informed consent
  2. Exclusion criteria:

    • Age extremes (less than 18 years old or more than 65 years old).
    • Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
    • Unknown medical history.

    Study Groups:

    • Group 1 (Cases): Patients known to have Cancer cervix with any degree of malignancy (diagnosed by routine screening or any other diagnostic tests)
    • Group 2 (Controls): Women sharing the same inclusion and exclusion criteria, but not known to have Cancer cervix

    Aim of The Study:

    1. Studying the role of HPV as an example of small DNA viruses in cell transformation and carcinogenesis.
    2. Determining the most HPV genotypes associated with high risks of cancer cervix occurrence.
    3. Detection of the HPV oncogenes playing role cell transformation and malignancy.
    4. Studying the role of viral DNA integration in cellular transformation and carcinogenesis.

      Study methods:

      Samples collection and storing:

      • Samples will be obtained from the cervix with the brush or swab\ by following the instructions corresponding to the type of collecting device.
      • Collection tubes will be stored at room temperature (15-30 °C).
      • Samples will be sent to the laboratory in less than 14 days following collection
      • The tubes can be preserved for 2-3 weeks at room temperature.

      HPV detection:

      • HPV cannot be propagated in tissue culture, and therefore, in most cases its accurate identification relies on molecular biology techniques, such as polymerase chain reaction (PCR).

      HPV Genotyping:

      • PCR-RFLP shows good discriminatory power by differentiating between HR and LR HPV genotypes, and it is possible to identify single or multiple infections .
      • In this technique, the amplified DNA is digested by restriction enzymes, resulting in DNA fragments of various lengths. Each fragment length is characteristic of a certain HPV genotype.
      • The commonest restriction enzymes are BamHI, Dd6eI, HaeIII, HinfI, PstI and RsaI.

      HPV Oncogenes and oncoproteins:

      • The main techniques used to detect mRNA for E6/E7 oncogenes are two commercial assays: PreTectW Proofer and APTIMAW HPV Assay. These techniques are based on transcription-mediated amplification of full-length E6/E7 transcripts using PCR.

      Statistical analysis:

      • Data will be analyzed by one-way analysis of variance using SPSS software version 24.0. Values will be expressed as mean ± S.D. For comparison between 2 groups, Student's t test will be used to determine whether the cases was significantly different from the control. Differences will be considered statistically significant at P\<0.05, while P\<0.01 will represent more significant change.
02

Conditions studied

  • DNA Virus Infections

Browse trials for

03

In context

Carcinogenesis

39 studies on the registry are indexed under Carcinogenesis; 10 are open to participants now.

This study's planned enrollment of 40 is below the median of 70 across 14 interventional studies indexed under Carcinogenesis.

Browse Carcinogenesis studies →

Lead sponsor

Heba Momen kamel is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: 18 - 65 years old.
  • Women who are positive for HPV diagnosed by routine screening.
  • Women willing to participate in the study and sign an informed consent

Exclusion criteria

Exclusion Criteria:

  • Age extremes (less than 18 years old or more than 65 years old).
  • Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
  • Unknown medical history.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    cases

    HPV detection HPV Genotyping HPV Oncogenes and oncoproteins

    Genetic: HPV oncogenes

  • Active comparator
    control

    HPV detection HPV Genotyping HPV Oncogenes and oncoproteins

    Genetic: HPV oncogenes

Interventions

  • GeneticHPV oncogenes

    PCR and oncogenes detection

06

What researchers measure

Primary outcomes

  1. carcinogenesis

    developing cancer cervix

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03188315
Lead sponsor
Heba Momen kamel
Responsible party
Heba Momen kamel (assistant lecturer, Assiut University) — Sponsor-investigator
First posted
Jun 15, 2017
Start date
Sep 1, 2017 (estimated)
Primary completion
Feb 28, 2018 (estimated)
Completion
Feb 28, 2018 (estimated)
Last update
Jun 15, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion